Abstract

Many US states now embrace the medical and recreational use of Cannabis. Changes in the laws have heightened interest and encouraged research into both cannabinoid products and the potential harms of Cannabis use, addiction and intoxication. The major active ingredient of Cannabis sativa (marijuana), Δ⁹-tetrahydrocannabinol (THC) and it powerfully stimulates the type-1 cannabinoid (CB₁) receptor. When used in the form of the plant marijuana, because of the many compounds that exist in the plant form they could inhibit the activity of the CB₁ receptor thereby reducing many of the effects of THC. While this mechanism seems correct, in our opinion, Vallee., et al. incorrectly suggest that blocking CB₁ receptors could open unforeseen approaches to the treatment of cannabis intoxication and addiction. We caution the scientific community that, other CB₁ receptor blockers, such as, Rimonabant (SR141718) have been pulled off the market in Europe. In addition, CB₁ receptor blockers were rejected by the FDA due to mood changes including suicide ideation. We argue that one issue facing the scientific community, has to do with the increasing legalization of Cannabis products in many states across America. We are in favor of some reform in terms of either decriminalization or restrictive legalization especially in control of legal limits of THC. Like other psychoactive compounds at high doses, it is our hypothesis that chronic use of these drugs including high THC content in its various forms (wax, smoke or vapor) resulting in brain reward dysfunction induces an imbalance of neurotransmission and subsequent hypodopaminergia and lead to aberrant substance and non-substance (behavioral) addictions. It is further proposed that in order to overcome THC and even other psychoactive drugs of abuse induced anhedonia the coupling of genetic risk testing and pro dopamine regulation is warranted.

Keywords: Cannabis Use Disorder (CUD); Cannabis sativa; Δ⁹-tetrahydrocannabinol (THC); Type-1 Cannabinoid (CB₁) Receptor

References

1. Lapham GT., et al. “The prevalence of Healthcare Effectiveness Data and Information Set (HEDIS) initiation and engagement in treatment among patients with cannabis use disorders in 7 US health systems”. Substance Abuse 3 (2019): 268-277.
2. Blum K., et al. “Cannabis-induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans in the Face of Legalization or Decriminalization: Putative Induction of Dopamine Homeostasis”. Journal: Frontiers in Psychiatry, section Addictive Disorders (2021).
3. Rubino T., et al. “Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates”. Neuropsychopharmacology 11 (2008): 2760-2771.
4. Blum K., et al. “Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence”. Frontiers in Bioscience (2018): 175-196.
5. Blum K., et al. “Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)”. Journal of Systems and Integrative Neuroscience (2020).
6. Blum K., et al. “Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)”. CPQ Neurology and Psychology's 2 (2018).
7. Gold MS., et al. “Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?” Journal of the Neurological Sciences 418 (2020): 117137.
8. Febo M., et al. “Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z”. PLoS One4 (2017): e0174774.
9. Willuhn I., et al. “Excessive cocaine use results from decreased phasic dopamine signaling in the striatum”. Nature Neuroscience 5 (2014): 704-709.
10. Tomasi D., et al. “Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors”. Human Brain Mapping 1 (2015): 120-136.
11. Blum K., et al. “rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts”. Postgraduate Medical Journal 2 (2015): 232-241.
12. Blum K., et al. “Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors”. Frontiers in Psychiatry 9 (2018): 548.
13. Blum K., et al. “Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2”. Postgraduate Medical Journal 6 (2010): 214-226.
14. Miller DK., et al. “Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports”. Postgraduate Medical Journal 6 (2010): 188-213.
15. Blessing EM., et al. “Cannabidiol as a Potential Treatment for Anxiety Disorders”. Neurotherapeutics4 (2015): 825-836.
16. Roeckel LA., et al. “CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid Receptors”. Front Psychiatry 9 (2018): 630.
17. Blum K., et al. “Tetrahydrocannabinol: Inhibition of alcohol induced withdrawal symptoms in mice”. In: Singh JM, Lal H, ed. Drug Addiction”. Neurobiology and Influences on Behavior 3 (1974): 39-53.
18. Hurd YL., et al. “Cannabis and the Developing Brain: Insights into Its Long-Lasting Effects”. The Journal of Neuroscience 42 (2019): 8250-8258.
19. Gu B., et al. “Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice”. Journal of Clinical Investigation 12 (2019): 5462-5467.